Swiss stocks - Factors to watch on October 14

By Reuters News

ZURICH/GDANSK, Oct 14 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday:

COMPANY STATEMENTS


LONZA GROUP AG LONN.S

The company upgraded, as part of its capital markets day, its organic growth model, now expecting to reach a core EBITDA margin in the high thirties in the mid-term.


GALDERMA GROUP AG GALD.S

Swiss skincare conglomerate Galderma GALD.S has agreed to buy medical-grade skincare company ZO Skin Health for around $1.5 billion, according to two people familiar with the matter.


UBS GROUP AG UBSG.S

A committee in Switzerland's upper house of parliament on Tuesday backed a government plan to create a public liquidity backstop for systemically important banks that would levy a fee on UBS UBSG.S to access it.


BOSSARD HOLDING AG BOS.S

The company said it reached for the third quarter group sales of 296.1 million Swiss francs ($356.06 million), up 12.0% year-on-year


ANALYSTS' VIEWS

SWISS RE AG SRENH.S : JEFFERIES CUTS TO UNDERPERFORM FROM HOLD; CUTS TARGET PRICE TO CHF 110 FROM CHF 130


ECONOMY

Swiss Bond Auction due at 0900 GMT.

SNB US Dollar auction due at 1000 GMT




($1 = 0.8316 Swiss francs)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.